ArticleNature reviews. Neurology2020
In search of an anti-inflammatory drug for Alzheimer disease.
Article in Nature reviews. Neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Inhibition of p38α MAPK increases short-term astrocyte reactivity: the exploratory VIP trial in early Alzheimer's disease.Journal of neuroinflammation · 2025Trial
- A review of the roles of pathogens in Alzheimer's disease.Frontiers in neuroscience · 2024Review
- Insights from the neural guidance factor Netrin-1 into neurodegeneration and other diseases.Frontiers in molecular neuroscience · 2024Review
- Evaluation of chalcone derivatives for their role as antiparasitic and neuroprotectant in experimentally induced cerebral malaria mouse model.3 Biotech · 2023Article
- A New Generation of IMiDs as Treatments for Neuroinflammatory and Neurodegenerative Disorders.Biomolecules · 2023Review
- Role of chronic neuroinflammation in neuroplasticity and cognitive function: A hypothesis.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2022Article
- Activity of a Novel Anti-Inflammatory Agent F-3,6'-dithiopomalidomide as a Treatment for Traumatic Brain Injury.Biomedicines · 2022Article
- Characterisation of the Mouse Cerebellar Proteome in the GFAP-IL6 Model of Chronic Neuroinflammation.Cerebellum (London, England) · 2022Article
- Challenges of repurposing tetracyclines for the treatment of Alzheimer's and Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2022Review
- Lipidomics in Understanding Pathophysiology and Pharmacologic Effects in Inflammatory Diseases: Considerations for Drug Development.Metabolites · 2022Review
- Potential of nobiletin against Alzheimer's disease through inhibiting neuroinflammation.Metabolic brain disease · 2022Article
- Enantioselective Synthesis and Pharmacological Evaluation of Aza-CGP37157-Lipoic Acid Hybrids for the Treatment of Alzheimer's Disease.Antioxidants (Basel, Switzerland) · 2022Article
- Editorial: Role of Inflammation in Neurodegenerative Diseases.Frontiers in immunology · 2022Article
- Curcumin-Piperlongumine Hybrids with a Multitarget Profile Elicit Neuroprotection in In Vitro Models of Oxidative Stress and Hyperphosphorylation.Antioxidants (Basel, Switzerland) · 2021Article
- Neuroinflammation in neurological disorders: pharmacotherapeutic targets from bench to bedside.Metabolic brain disease · 2021Review
- New therapeutics beyond amyloid-β and tau for the treatment of Alzheimer's disease.Acta pharmacologica Sinica · 2021Review
- Article
- Recent advances on drug development and emerging therapeutic agents for Alzheimer's disease.Molecular biology reports · 2021Review
- SIRT1-Dependent Upregulation of BDNF in Human Microglia Challenged with Aβ: An Early but Transient Response Rescued by Melatonin.Biomedicines · 2021Article
- Article
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
31919414What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.